Chimericantigenreceptor相关论文
...
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and
c-Met is a hepatocyte growth factor receptor overexpressed in many tumors such as hepatocellular carcinoma(HCC).Therefor......
目的:探索开发一种靶向CLL-1的嵌合抗原受体T细胞（CAR-T细胞）并验证其功能。方法:通过流式细胞术检测急性髓系白血病（AML）细胞系和AML......
Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy ass
Cytokine release syndrome (CRS) is a major obstacle to the widespread clinical application of chimeric antigen receptor ......
急性淋巴细胞白血病(acute lymphoblastic leukemia，ALL)是儿童时期最常见的恶性肿瘤，其中急性T淋巴细胞白血病(T-ALL)占儿童ALL的10......
Noninvasive tracking the kinetic phases of distribution and glioma targeting of EGFRvⅢ-specific chim
Purpose Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults and is uniformly lethal......
...
...
T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer st
...
Adoptive cell Therapy using T cells Engineered with Dual Signal-independent Chimeric Antigen Recepto
Objective: Chimeric antigen receptor (CAR)-engineered T cells (CAR-T) can destroy tumor cells expressing targeted tumor-......
Antitumor activity of EGFR-specific CAR-T cells against non-small-cell lung cancer cells in vitro an
Objectives:Effective controls of non-small lung cancer(NSCLC) are still a clinical challenge,especially advanced stages ......
Engineered human pluripotent stem cell-derived natural killer cells: the next frontier for cancer im
...
妄想的抗原获得的成功在 hematological 恶意的修改受体的 T (大车) 房间在非小的肺癌症(NSCLC ) 提起了他们的使用的可能性。在这......
随着肿瘤免疫学理论和技术的不断发展,人们对肿瘤的认识和治疗也迎来了新纪元.除了传统的手术、放疗和化疗以外,以嵌合抗原受体修......
儿童肿瘤患者的5年生存率已达80%以上,但仍有部分复发难治性肿瘤通过传统治疗手段难以取得理想疗效.嵌合抗原受体(CAR)-T细胞技术......
儿童恶性肿瘤的发病率逐年升高，传统治疗手段的疗效有限，因此急需一种新的治疗方案来提高存活率。免疫治疗是一种新的治疗方法，其中一......
Impaired tumor-specific effector T cells contribute to tumor progression and unfavorable clinical outcomes.As a compensa......
近年来在肿瘤免疫治疗领域，嵌合抗原受体（CAR）修饰T细胞在基础研究和临床试验中取得了巨大进展。CAR由特异性单克隆抗体的可变区和CD3......
